Sean Maduck - 01 Sep 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Officer
Issuer ticker: CORT
Reported as of: 01 Sep 2026
Net transaction value: -$2,860,737
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:16:42 UTC
Prior SEC filing: 27 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck

Key filing fact

Sean Maduck filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 03 Sep 2026.

Key facts

This page summarizes Sean Maduck's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
8 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Sep 2026, 21:16.

Change

Previous filing in this sequence was filed on 27 Aug 2026.
Current net transaction value: -$2,860,737.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001698310 Primary reporting owner

Maduck Sean

Relationship: Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,000
Change %: +256%
Price: $8.27^*
Shares after: 34,755
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

CORT transaction

Common Stock

Sale

Transaction value: $1,336,459
Shares: -11,730
Change %: -34%
Price: $113.94
Shares after: 23,025
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

CORT transaction

Common Stock

Sale

Transaction value: $1,260,568
Shares: -10,989
Change %: -48%
Price: $114.71
Shares after: 12,036
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F4

CORT transaction

Common Stock

Sale

Transaction value: $263,711
Shares: -2,281
Change %: -19%
Price: $115.61
Shares after: 9,755
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F5

CORT transaction

Common Stock

Award

Transaction value
Shares: +150
Change %: +1.5%
Price: $113.38^*
Shares after: 9,905
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F6, F7

CORT transaction

Common Stock

Award

Transaction value
Shares: +150
Change %: +1.5%
Price: $0.000000^*
Shares after: 10,055
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F8

CORT transaction

Common Stock

Tax liability

Transaction value
Shares: -117
Change %: -1.2%
Price: $113.38^*
Shares after: 9,938
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F9, F10, F11

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,147
Date: 01 Sep 2026
Ownership: See Footnote
Footnotes: F12

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,570
Date: 01 Sep 2026
Ownership: See Footnote
Footnotes: F13

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 01 Sep 2026
Ownership: See Footnote
Footnotes: F14

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 34,000
Date: 01 Sep 2026
Ownership: See Footnote
Footnotes: F15

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 01 Sep 2026
Ownership: See Footnote
Footnotes: F16

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CORT transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value
Shares: -25,000
Change %: -27%
Price: $0.000000^*
Shares after: 66,986
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $8.27
Footnotes: F17

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 17 footnotes

Footnote F1

Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F2

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

Footnote F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F5

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F6

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

Footnote F7

In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

Footnote F8

Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Footnote F9

These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

Footnote F10

The closing price on September 1, 2026 was used to calculate the withholding obligation.

Footnote F11

Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F12

Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

Footnote F13

Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

Footnote F14

Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

Footnote F15

Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

Footnote F16

Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Footnote F17

Fully exercisable.

SEC remarks

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .